Research programme: anti-SDF-1 antibodies - RegenMed
Latest Information Update: 16 Jul 2016
At a glance
- Originator RegenMed
- Mechanism of Action Chemokine receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Diabetic retinopathy
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetic-retinopathy in USA
- 20 Feb 2006 Preclinical trials in Diabetic retinopathy in USA (unspecified route)